# Dalteparin

## FRAGMIN 10000 IU(Anti-Xa)/4mL

| TAH Drug Code      | [IFRA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFRA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of acute deep venous thrombosis. Prevention of clotting in the extracorporeal system during hemodialysis & hemofiltration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Thrombolysis or treatment of acute deep vein thrombosis and pulmonary embolism not suitable for surgical treatment: SC once daily 200 IU/kg or twice daily 100 IU/kg, up to 18000 IU. Prophylaxis of coagulation during hemodialysis and hemofiltration, IV initial dose of 30-40 IU/kg then 10-15 IU/kg every hour. Prophylaxis to patients with substantially increased risk of venous thromboembolism & that are temporarily immobilized due to acute illness such as cardiac/respiratory insufficiency, severe infections 5000 IU SC once daily for 12-14 days or longer in patients with restricted mobility. Treatment of acute deep venous thrombosis & pulmonary embolism & extended thromboprophylaxis in cancer patients 200 IU/kg SC once daily for first month of treatment. Maximum daily dose: 18,000 IU . 150 IU/kg SC once daily for months 2-6. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Confirmed or suspected history of immunologically-mediated heparin-induced thrombocytopenia. Active, clinically significant bleeding (eg. GI ulceration or bleeding or cerebral hemorrhage). Severe coagulation disorders, septic endocarditis. Recent injury to, or surgical procedures of, the CNS, eyes &/or ears.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | Reversible non-immunologically-mediated thrombocytopenia (type 1), transient elevation of liver transaminases, bleeding, hematoma at inj site, allergic reactions, pain at inj site. Dermatologic: Hematoma, Injection site (7% to 35%), Injection site pain (4.5% to 12% ) Hematologic: Hematoma Other: Irritation symptom, Local                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Pregnancy          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## Fragmin inj 5000 IU/0.2mL single dose syringe

| TAH Drug Code      | [IFRA5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFRA5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of acute deep venous thrombosis. Deep venous thrombosis, In medical patients with severely restricted mobility due to acute illness; Prophylaxis. Postoperative deep vein thrombosis; Prophylaxis - Total replacement of hip. Venous thromboembolism, Symptomatic.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Prophylaxis of venous thromboembolism during surgical procedures: Usually: 2500 IU given 2 hours before the procedure followed by 2500 IU once daily for 5-7 days or until the patient is fully ambulant. High-risk patients: 2500 IU given 2 hours before and 8-12 hours after the procedure, and followed by 5000 IU daily for 5-10 days. Or 5000 IU single dose in the evening before the procedure, and followed by 5000 IU every evening 5-10 days. Orthopedic surgery (for example, hip replacement surgery): up to 5 weeks. 5000 IU given in the evening before surgery followed by 5000 IU each subsequent evening. Or 2500 IU given 2 hours before and 8-12 hours after the procedure, and followed by 5000 IU daily. Or 2500 IU 4-8 hours after the procedure, and followed by 5000 IU daily. Venous thromboembolism Initial, 200 IU/kg every 24 hours for the first 30 days, followed by 150 IU/kg(= or <56kg: 7500 IU; 57-68kg:10000 IU; 69-82kg: 12500 IU; 83-98kg: 15000 IU; > or =99kg: 18000 IU) every 24 hours during months 2 to 6; Maximum daily dose, 18000 IU/day. Deep venous thrombosis, In medical patients with severely restricted mobility due to acute illness; Prophylaxis 5000 IU once daily for 12 to 14 days. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Active major bleeding. History of heparin-induced thrombocytopenia with or without thrombosis. Hypersensitivity to dalteparin sodium, heparin, or pork products. In patients undergoing epidural or neuraxial anesthesia do not administer dalteparin for unstable angina, non-Q-wave myocardial infarction, or prolonged VTE prophylaxis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common Dermatologic: Contusion (12% ), Hematoma, Injection site (7% to 35%), Injection site bruising (30% ), Injection site pain (4.5% to 12% ) Respiratory: Bleeding from nose (10% ) Other: Irritation symptom, Local Serious Hematologic: Extradural intracranial hematoma, Hematoma, Spinal, Hemorrhage, Major (Up to 13.6%), Hemorrhagic cerebral infarction (8% ), Intracranial hemorrhage, Subdural hemorrhage, Intrauterine, Thrombocytopenia (Adult, non-cancer indications, less than 1%; patients with cancer, 10.9% to 13.6% ; pediatric, 21% ) Hepatic: Increased liver function test (up to 4.3%) Immunologic: Anaphylactoid reaction (rare) Neurologic: Paralysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pregnancy          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

